ABL DiagnosticsXPAR:ABLD +0.76%51 PB Ratio is 5.60 as of Jul. 06, 2026, which is 405% above its 10-year median of 1.11. GuruFocus rates XPAR:ABLD with a GF Score™ of 51/100 and a GF Value™ of €7.71 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 607 Healthcare Providers & Services companies, ABL Diagnostics ranks worse than 82.21% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-06), ABL Diagnostics's share price is €2.66. ABL Diagnostics's Book Value per Share for the quarter that ended in Dec. 2025 was €0.48. Hence, ABL Diagnostics's PB Ratio of today is 5.60.
Good Sign:
ABL Diagnostics stock PB Ratio (=5.6) is close to 3-year low of 5.05.
The historical rank and industry rank for ABL Diagnostics's PB Ratio or its related term are showing as below:
XPAR:ABLD'
s PB Ratio Range Over the Past 10 Years
Min: 0.36 Med: 1.11 Max: 34.49
Current: 5.6
During the past 13 years, ABL Diagnostics's highest PB Ratio was 34.49. The lowest was 0.36. And the median was 1.11.
XPAR:ABLD's PB Ratio is ranked worse than 82.21% of 607
companies
in the Healthcare Providers & Services industry
Industry Median: 2.02
vs XPAR:ABLD: 5.60
During the past 12 months, ABL Diagnostics's average Book Value Per Share Growth Rate was 2.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 4.30% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -19.60% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -23.50% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of ABL Diagnostics was 8.30% per year. The lowest was -50.90% per year. And the median was 1.60% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
ABL Diagnostics PB Ratio Related Terms
ABL Diagnostics PB Ratio Historical Data
* Premium members only.
The historical data trend for ABL Diagnostics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, ABL Diagnostics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ABL Diagnostics PB Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, ABL Diagnostics's PB Ratio distribution charts can be found below:
* The bar in red indicates where ABL Diagnostics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
ABL Diagnostics's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
ABL Diagnostics (XPAR:ABLD) has a PB Ratio of 5.60 as of Jul. 06, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on ABL Diagnostics and its competitors. This is 405% above median its historical median of 1.11. Over the past decade, ABL Diagnostics' PB Ratio has ranged from 0.36 to 34.49. According to the industry distribution chart, ABL Diagnostics ranks #499 out of 607 companies in the Healthcare Providers & Services industry, placing it in the top 82.2%.
Is ABL Diagnostics' PB Ratio too high?
ABL Diagnostics' current PB Ratio of 5.60 is 405% above median its 10-year median of 1.11. Over the past 10 years, this metric has ranged from a low of 0.36 to a high of 34.49. The Healthcare Providers & Services industry median PB Ratio is 2.02. ABL Diagnostics' value of 5.60 is 177.2% above this industry median. Based on the distribution chart, ABL Diagnostics ranks #499 out of 607 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, ABL Diagnostics has a GF Score™ of 51/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ABL Diagnostics' PB Ratio compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, ABL Diagnostics ranks #499 out of 607 companies for PB Ratio. This places ABL Diagnostics in the lower half of its industry. The industry median PB Ratio is 2.02. ABL Diagnostics' value of 5.60 is 177.2% above this benchmark. Historically, ABL Diagnostics' own PB Ratio has ranged from 0.36 to 34.49 over the past decade. While the company's 10-year median is 1.11 vs. the industry median of 2.02, ABL Diagnostics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Healthcare Providers & Services company?
The median PB Ratio among Healthcare Providers & Services companies is 2.02, based on 607 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ABL Diagnostics's current PB Ratio of 5.60 is 177.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on ABL Diagnostics and its competitors. For the Healthcare Providers & Services industry, the median PB Ratio is 2.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ABL Diagnostics's current PB Ratio is 5.60, which is 405% above median its own 10-year median of 1.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ABL Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, ABL Diagnostics (XPAR:ABLD) is currently considered Significantly Undervalued. The stock's GF Value™ is €7.71, compared to a current price of €2.66 — trading 65.5% below its estimated fair value. The current PB Ratio is 5.60, which is 405% above median its 10-year median of 1.11 and 177.2% above the Healthcare Providers & Services industry median of 2.02. ABL Diagnostics' overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For ABL Diagnostics (XPAR:ABLD), the current PB Ratio is 5.60 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ABL Diagnostics (XPAR:ABLD) Overvalued in 2026?
Based on GuruFocus' analysis, ABL Diagnostics stock appears to be undervalued.
The current stock price of €2.66 is trading 65.5% below its estimated GF Value™ of €7.71.
GuruFocus considers ABL Diagnostics to be Significantly Undervalued.
Key valuation signals for XPAR:ABLD:
PB Ratio: 5.60 (405% above median its 10-year median of 1.11)
GF Value™: €7.71 vs. price of €2.66 (65.5% below fair value)
Industry Position: 177.2% above the Healthcare Providers & Services median (#499 of 607)
No single metric tells the full story. See the XPAR:ABLD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ABL Diagnostics is a diagnostic and medical software company. The group has focused on the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. It also develops, manufactures, and markets kits for clinical specimen collection.
51GF Score
Get the complete analysis for XPAR:ABLD
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ABLD has been successfully added to your 
